Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + decasaccharide
?
-
-
-
-
r
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
24% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
270% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
260% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal-Gal(6S)beta(1->4)Xyl-ol
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xyl-ol
360% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl(2P)-ol
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->3)GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)-Galbeta(1->4)Xyl(2P)-ol
290% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + DELTA4HexUAalpha(1->4)GlcNAc(6S)-GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + DELTA4HexUAalpha(1->4)GlcNAc(6S)beta(1->3)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
17% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + dodecasaccharide
?
-
-
-
-
r
3'-phosphoadenylyl sulfate + Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
4% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GalNAcbeta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GalNAc(6S)beta(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
84% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcNAcalpha(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcNAcalpha(1->4)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
2% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)Gal(4S)beta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)Gal(4S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
20% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
8% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)GalNAc(4S)beta(1->4)GlcUAbeta(1->3)Gal(4S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
250% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + GlcUAbeta(1->3)GalNAcbeta(1->4)GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xylbeta(1->O)-Ser
adenosine 3',5'-bisphosphate + GlcUAbeta(1->3)GalNAc(6S)beta(1->3)GlcUAbeta(1->3)Gal(6S)beta(1->3)Gal(6S)beta(1->4)Xylbeta(1->O)-Ser
130% of the activity with GlcUAbeta(1->3)Galbeta(1->3)Galbeta(1->4)Xyl-(Gly)Ser-(Gly-Glu)
-
-
?
3'-phosphoadenylyl sulfate + hexasaccharide
?
-
-
-
-
r
3'-phosphoadenylyl sulfate + keratan sulfate
?
-
-
-
?
3'-phosphoadenylyl sulfate + native chondroitin
adenosine 3',5'-bisphosphate + native chondroitin sulfate
-
-
-
-
r
3'-phosphoadenylyl sulfate + octasaccharide
?
-
-
-
-
r
3'-phosphoadenylylsulfate + 1-phospho-N-acetylgalactosamine 4-sulfate
adenosine 3',5'-bisphosphate + 1-phospho-N-acetylgalactosamine 4,6-bissulfate
-
-
-
?
3'-phosphoadenylylsulfate + beta-benzyl N-acetylglucosamine
adenosine 3',5'-bisphosphate + beta-benzyl N-acetylglucosaminesulfate
-
enzyme does not use alpha-or beta-benzyl N-acetylgalactosamine
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
3'-phosphoadenylylsulfate + chondroitin 4-sulfate
adenosine 3',5'-bisphosphate + chondroitin 4,6-bissulfate
3'-phosphoadenylylsulfate + chondroitin sulfate A
adenosine 3',5'-bisphosphate + ?
-
6.2% of the activity with chondroitin
-
-
?
3'-phosphoadenylylsulfate + chondroitin sulfate C
adenosine 3',5'-bisphosphate + ?
-
3% of the activity with chondroitin
-
-
?
3'-phosphoadenylylsulfate + chondroitin-derived oligosaccharides
?
3'-phosphoadenylylsulfate + corneal keratan sulfate
?
3'-phosphoadenylylsulfate + desulfated dermatan sulfate
adenosine 3',5'-bisphosphate + ?
-
95% of the activity with chondroitin
-
-
?
3'-phosphoadenylylsulfate + N-acetylgalactosamine 4-sulfate
adenosine 3',5'-bisphosphate + N-acetylgalactosamine 4,6-bissulfate
-
-
-
?
3'-phosphoadenylylsulfate + phenyl 2-acetamido-2-deoxy-4-O-sulfonato-D-galactopyranose
adenosine 3',5'-bisphosphate + phenyl 2-acetamido-2-deoxy-4,6-di-O-sulfonato-D-galactopyranose
-
-
-
-
?
3'-phosphoadenylylsulfate + UDP-N-acetylgalactosamine 4-sulfate
adenosine 3',5'-bisphosphate + UDP-N-acetylgalactosamine 4,6-bissulfate
-
-
-
?
adenosine 3',5'-bisphosphate + desulfated chondroitin sulfate
3'-phosphoadenylyl sulfate + desulfated chondroitin
-
-
-
-
r
additional information
?
-
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
specificity towards desulfated chondroitin sulfate and oligosaccharides derived therefrom
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
is believed to act in the course of chondroitin sulfate synthesis in cooperation with, but shortly after the enzymes involved in the chain elongation reaction
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
involved in biosynthesis of chondroitin sulfate
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
incorporates sulfate exclusively into GalNAc C-6 position
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
incorporates sulfate exclusively into GalNAc C-6 position
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
native chondroitin is the best acceptor, chemically desulfated chondroitin sulfate has the lowest rate of sulfation
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
involved in the maintenance of native T lymphocytes in the spleen
-
?
3'-phosphoadenylylsulfate + chondroitin 4-sulfate
adenosine 3',5'-bisphosphate + chondroitin 4,6-bissulfate
-
incorporates sulfate into position 6 of the nonreducing N-acetylgalactosamine 4-sulfate end group of chondroitin, no activity with unsulfated chondroitin
-
?
3'-phosphoadenylylsulfate + chondroitin 4-sulfate
adenosine 3',5'-bisphosphate + chondroitin 4,6-bissulfate
-
may play a role in synthesis of proteoglycans
-
-
?
3'-phosphoadenylylsulfate + chondroitin 4-sulfate
adenosine 3',5'-bisphosphate + chondroitin 4,6-bissulfate
-
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin-derived oligosaccharides
?
-
even-numbered oligosaccharides with a glucuronic acid at the nonreducing terminus are active as acceptors, their capacity decreasing with decreasing chain length: dodecasaccharide at 64%, decasaccharide at 55%, octasaccharide at 17%, hexasaccharide at 4% of the chondroitin sulfation
-
-
?
3'-phosphoadenylylsulfate + chondroitin-derived oligosaccharides
?
-
-
-
-
?
3'-phosphoadenylylsulfate + corneal keratan sulfate
?
-
-
-
-
?
3'-phosphoadenylylsulfate + corneal keratan sulfate
?
-
-
-
?
3'-phosphoadenylylsulfate + corneal keratan sulfate
?
-
-
sulfated product is degraded by keratanase but not by chondroitinase ABC
?
3'-phosphoadenylylsulfate + corneal keratan sulfate
?
transfers sulfate to position 6 of Gal residues
-
-
?
3'-phosphoadenylylsulfate + corneal keratan sulfate
?
-
-
-
?
additional information
?
-
-
no substrate: GDPmannose
-
-
?
additional information
?
-
-
no substrate: UDP-N-acetylglucosamine 6-sulfate
-
-
?
additional information
?
-
-
no substrate: UDPgalactose
-
-
?
additional information
?
-
-
no substrate: UDP-N-acetylgalactosamine
-
-
?
additional information
?
-
-
no substrate: heparin
-
-
?
additional information
?
-
-
no substrate: heparan sulfate
-
-
?
additional information
?
-
-
no substrate: UDP-N-acetylglucosamine
-
-
?
additional information
?
-
-
no substrate: UDP-N-acetylgalactosamine 6-sulfate
-
-
?
additional information
?
-
-
overview: sulfation of sialyl lactosamine oligosaccharides
-
-
?
additional information
?
-
-
does not sulfate a non-reducing terminal GalNAc residue when this residue is added concurrently with the sulfation
-
-
?
additional information
?
-
overview: sulfation of chondroitin sulfates
-
-
?
additional information
?
-
-
overview: sulfation of chondroitin sulfates
-
-
?
additional information
?
-
keratan sulfate and oligosaccharides containing the Galbeta1-4GlcNAc sequence hardly serve as acceptors for C6ST-2
-
-
?
additional information
?
-
-
keratan sulfate and oligosaccharides containing the Galbeta1-4GlcNAc sequence hardly serve as acceptors for C6ST-2
-
-
?
additional information
?
-
-
no substrate: dermatan sulfate. Enzyme mainly transfers sulfate to GalNAc residues located in the L-iduronic acid rich region with little preference for the GalNAc residue neighbouring the GlcA residue
-
-
?
additional information
?
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
additional information
?
-
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
additional information
?
-
-
no substrate: hyaluronate
-
-
?
additional information
?
-
-
no substrate: heparin
-
-
?
additional information
?
-
-
dermatan sulfate and keratan sulfate preparations which contain covalently bound chondroitin sulfate act as sulfate acceptors
-
-
?
additional information
?
-
upregulation of chondroitin 6-sulphotransferase-1 facilitates Schwann cell migration during axonal growth, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + keratan sulfate
?
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
3'-phosphoadenylylsulfate + chondroitin 4-sulfate
adenosine 3',5'-bisphosphate + chondroitin 4,6-bissulfate
-
may play a role in synthesis of proteoglycans
-
-
?
additional information
?
-
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylyl sulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
is believed to act in the course of chondroitin sulfate synthesis in cooperation with, but shortly after the enzymes involved in the chain elongation reaction
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
involved in biosynthesis of chondroitin sulfate
-
-
?
3'-phosphoadenylylsulfate + chondroitin
adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate
-
involved in the maintenance of native T lymphocytes in the spleen
-
?
additional information
?
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
additional information
?
-
-
the enzyme mediates the sulfation of proteoglycans, particularly chondroitin sulfate, in the extracellular matrix of cartilage
-
-
?
additional information
?
-
upregulation of chondroitin 6-sulphotransferase-1 facilitates Schwann cell migration during axonal growth, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Molecular cloning, expression, and chromosomal mapping of human chondroitin 4-sulfotransferase, whose expression pattern in human tissues is different from that of chondroitin 6-sulfotransferase.
Atherosclerosis
Human chondroitin 6-sulfotransferase: cloning, gene structure, and chromosomal localization.
Brain Injuries
Chondroitin 6-sulphate synthesis is up-regulated in injured CNS, induced by injury-related cytokines and enhanced in axon-growth inhibitory glia.
chondroitin 6-sulfotransferase deficiency
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis.
chondroitin 6-sulfotransferase deficiency
Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features.
Clubfoot
A novel CHST3 allele associated with Spondyloepiphyseal dysplasia and hearing loss in Pakistani kindred.
Contracture
A novel CHST3 allele associated with Spondyloepiphyseal dysplasia and hearing loss in Pakistani kindred.
Contracture
Recurrent c.776T>C mutation in CHST3 with four other novel mutations and a literature review.
Deafness
Spondyloepiphyseal dysplasia, Omani type: further definition of the phenotype.
Dysostoses
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis.
Dysostoses
Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features.
Glioma
OASIS regulates chondroitin 6-O-sulfotransferase 1 gene transcription in the injured adult mouse cerebral cortex.
Hearing Loss
A novel CHST3 allele associated with Spondyloepiphyseal dysplasia and hearing loss in Pakistani kindred.
Heart Septal Defects, Ventricular
Spondyloepiphyseal dysplasia, Omani type: further definition of the phenotype.
Hypertension
CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Intervertebral Disc Degeneration
Carbohydrate sulfotransferase 3 (CHST3) overexpression promotes cartilage endplate-derived stem cells (CESCs) to regulate molecular mechanisms related to repair of intervertebral disc degeneration by rat nucleus pulposus.
Intervertebral Disc Degeneration
Lumbar disc degeneration is linked to a carbohydrate sulfotransferase 3 variant.
Joint Dislocations
A novel CHST3 allele associated with Spondyloepiphyseal dysplasia and hearing loss in Pakistani kindred.
Joint Dislocations
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis.
Joint Dislocations
Prenatal homozygosity mapping detects a novel mutation in CHST3 in a fetus with skeletal dysplasia and joint dislocations.
Joint Dislocations
Recurrent c.776T>C mutation in CHST3 with four other novel mutations and a literature review.
Joint Dislocations
Spondyloepiphyseal dysplasia, Omani type: further definition of the phenotype.
Leukemia
Whole exome sequencing detects CHST3 mutation in patient with acute promyelocytic leukemia: A case report.
Leukemia, Promyelocytic, Acute
Whole exome sequencing detects CHST3 mutation in patient with acute promyelocytic leukemia: A case report.
Liver Diseases
Predictive model of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Neoplasms
Human chondroitin 6-sulfotransferase: cloning, gene structure, and chromosomal localization.
Osteochondrodysplasias
A novel CHST3 allele associated with Spondyloepiphyseal dysplasia and hearing loss in Pakistani kindred.
Osteochondrodysplasias
A novel nonsense mutation in CHST3 in a Turkish patient with spondyloepiphyseal dysplasia, Omani type.
Osteochondrodysplasias
Expanding the clinical spectrum of B4GALT7 deficiency: homozygous p.R270C mutation with founder effect causes Larsen of Reunion Island syndrome.
Osteochondrodysplasias
Omani-type spondyloepiphyseal dysplasia with cardiac involvement caused by a missense mutation in CHST3.
Osteochondrodysplasias
Spondyloepiphyseal dysplasia Omani type: CHST3 mutation spectrum and phenotypes in three Indian families.
Osteochondrodysplasias
Whole exome sequencing detects CHST3 mutation in patient with acute promyelocytic leukemia: A case report.
Paraplegia
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Psoriasis
Chondroitin 6-sulfate represses keratinocyte proliferation in mouse skin, which is associated with psoriasis.
Pulmonary Arterial Hypertension
CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension.
Pulmonary Emphysema
RNA interference targeting carbohydrate sulfotransferase 3 diminishes macrophage accumulation, inhibits MMP-9 expression and promotes lung recovery in murine pulmonary emphysema.
Seizures
Involvement of chondroitin 6-sulfation in temporal lobe epilepsy.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
L259P
naturally occuring mutation of CHST3 involved in enzyme deficiency and related disease
L286P
naturally occuring mutation of gene CHST3 causing the Spondyloepiphyseal dysplasia Omani type, almost inactive mutant, phenotype, overview
L307P
naturally occuring mutation of CHST3 involved in enzyme deficiency and related disease
R222W
naturally occuring mutation of CHST3 involved in enzyme deficiency and related disease
T141M
homozygous missense mutation leading to a reduction of C6ST-1 activity to 24-29% of the wild type enzyme, the naturally occuring missense mutation in exon 3 of gene CHST3 causes Omani-type spondyloepiphyseal dysplasia with cardiac involvement, phenotype with skeletal features, cardiac involvement including mitral, tricuspid and/or aortic regurgitations and type E brachydactyly, overview
N250S
site-directed mutagenesis, mutation of a putative N-glycosylation site, deletion of the fourth N-glycosylation site from the N-terminus of the enzyme inhibits production of the active C6ST-1, the mutant remains in the endoplasmic reticulum, while all other wild-type and mutant enzymes are located in the Golgi apparatus
N413S
site-directed mutagenesis, mutation of a putative N-glycosylation site, deletion of the fourth or sixth N-glycosylation site from the N-terminus of the enzyme inhibits production of the active C6ST-1
N457S
site-directed mutagenesis, mutation of a putative N-glycosylation site, deletion of the fifth N-glycosylation site from the N-terminus of the enzyme results in a marked loss of the keratan sulfate sulfotransferase activity
N63S
site-directed mutagenesis, mutation of a putative N-glycosylation site
N74S
site-directed mutagenesis, mutation of a putative N-glycosylation site
N96S
site-directed mutagenesis, mutation of a putative N-glycosylation site
R304Q
-
missense mutation found in patients with a distinct form of spondyloepiphyseal dysplasia, SED Omani type, complete loss of activity, resulting in significant reduction of both DELTAHexA-GalNAc(6S) and DELTAHexA(2S)-GalNAc(6S) and elevate levels of DELTAHexA-GalNAc(4S,6S)
R304Q
naturally occuring mutation of gene CHST3 causing the Spondyloepiphyseal dysplasia Omani type, phenotype, overview
additional information
identification of eight naturally occuring CHST3 mutations in six unrelated individuals who presented at birth with congenital joint dislocations with diagnosis of either Larsen syndrome or humero-spinal dysostosis, the patients show reduced enzyme activity and congenital dislocation of the knees, elbow joint dysplasia with subluxation and limited extension, hip dysplasia or dislocation, clubfoot, short stature, and kyphoscoliosis developing in late childhood, genotyping, enzyme mutant phenotypes, overview
additional information
-
identification of eight naturally occuring CHST3 mutations in six unrelated individuals who presented at birth with congenital joint dislocations with diagnosis of either Larsen syndrome or humero-spinal dysostosis, the patients show reduced enzyme activity and congenital dislocation of the knees, elbow joint dysplasia with subluxation and limited extension, hip dysplasia or dislocation, clubfoot, short stature, and kyphoscoliosis developing in late childhood, genotyping, enzyme mutant phenotypes, overview
additional information
enzyme knockout by siRNA
additional information
-
enzyme knockout by siRNA
additional information
enzyme upregulation facilitates Schwann cell migration during axonal growth, while enzyme downregulation accompanies declining mobility of Schwann cells as they engaged in the myelination of re-growing axons, overview
additional information
reconstitution of the chondroitin biosynthesis pathway in a recombinant Bacillus subtilis strain using sucrose as carbon source, method optimization, overview. Specific sulfation transformation systems are constructed and optimized by combining the purified aryl sulfotransferase IV (ASST IV, EC 2.8.2.1), chondroitin 4-sulfotransferase (C4ST, EC 2.8.2.5) and chondroitin 6-sulfotransferase (C6ST). Chondroitin sulfate A and C are enzymatically transformed from chondroitin at conversion rates of 98% and 96%, respectively. The ASST IV enzyme is used for PAPS regeneration. Purification of CS disaccharides by anion exchange chrmatography and NMR analysis of the composition of CS disaccharides
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Nakanishi, Y.; Shimizu, M.; Otsu, K.; Kato, S.; Tsuji, M.; Suzuki, S.
A terminal 6-sulfotransferase catalyzing a synthesis of N-acetylgalactosamine 4,6-bissulfate residue at the nonreducing terminal position of chondroitin sulfate
J. Biol. Chem.
256
5443-5449
1981
Coturnix japonica
brenda
Habuchi, O.; Miyashita, N.
Separation and characterization of chondroitin 6-sulfotransferase and chondroitin 4-sulfotransferase from chick embryo cartilage
Biochim. Biophys. Acta
717
414-421
1982
Gallus gallus
brenda
Sugumaran, G.; Silbert, J.E.
Sulfation of chondroitin. Specificity, degree of sulfation, and detergent effects with 4-sulfating and 6-sulfating microsomal systems
J. Biol. Chem.
263
4673-4678
1988
Gallus gallus
brenda
Sugumaran, G.; Cogburn, J.N.; Silbert, J.E.
Simultaneous sulfation of endogenous chondroitin sulfate and chondroitin-derived oligosaccharides. Studies with separate 4-sulfating and 6-sulfating microsomal systems
J. Biol. Chem.
261
12659-12664
1986
Gallus gallus
brenda
Habuchi, O.; Tsuzuki, M.; Takeuchi, I.; Hara, M.; Matsui, Y.; Ashikari, S.
Secretion of chondroitin 6-sulfotransferase and chondroitin 4-sulfotransferase from cultured chick embryo chondrocytes
Biochim. Biophys. Acta
1133
9-16
1991
Gallus gallus
brenda
Delfert, D.M.; Conrad, H.E.
Sulfation of chondroitin oligosaccharides in vitro. Analysis of sulfation ratios
J. Biol. Chem.
260
14446-14451
1985
Gallus gallus
brenda
Hollmann, J.; Niemann, R.; Buddecke, E.
Purification and characterization of a 3-phosphoadenylylsulfate:chondroitin 6-sulfotransferase from arterial tissue
Biol. Chem. Hoppe-Seyler
367
5-13
1986
Bos taurus
brenda
Salac, M.L.B.; Mourao, P.A.S.
Effects of detergents on the sulfation of chondroitin sulfate by sulfotransferase from chicken embryo epiphyseal cartilage
Biochim. Biophys. Acta
1074
130-135
1991
Gallus gallus
brenda
Habuchi, O.; Matsui, Y.; Kotoya, Y.; Aoyama, Y.; Yasuda, Y.; Noda, M.
Purification of chondroitin 6-sulfotransferase secreted from cultured chick embryo chondrocytes
J. Biol. Chem.
268
21968-21974
1993
Gallus gallus
brenda
Salac, M.L.B.; Santos, J.A.; Mourao, P.A.S.
Protamine increases the affinity of 3-phosphoadenosine 5-phosphosulfate toward a sulfotransferase from chicken embryo epiphyseal cartilage
Biochim. Biophys. Acta
883
605-609
1986
Gallus gallus
brenda
Momburg, M.; Stuhlsatz, H.W.; Greiling, H.
Isolation and substrate specificity of a 3-phosphoadenyl sulfate: chondroitin 6-sulfotransferase from mouse liver
Hoppe-Seyler's Z. Physiol. Chem.
353
1351-1361
1972
Mus musculus
brenda
Bhakta, S.; Bartes, A.; Bowman, K.G.; Kao, W.M.; Polsky, I.; Lee, J.K.; Cook, B.N.; Bruehl, R.E.; Rosen, S.D.; Bertozzi, C.R.; Hemmerich, S.
Sulfation of N-acetylglucosamine by chondroitin 6-sulfotransferase 2 (GST-5)
J. Biol. Chem.
275
40226-40234
2000
Homo sapiens, Mus musculus (Q9EP78), Mus musculus
brenda
Fukuta, M.; Kobayashi, Y.; Uchimura, K.; Kimata, K.; Habuchi, O.
Molecular cloning and expression of human chondroitin 6-sulfotransferase
Biochim. Biophys. Acta
1399
57-61
1998
Homo sapiens (Q7LGC8), Homo sapiens
brenda
Fukuta, M.; Uchimura, K.; Nakashima, K.; Kato, M.; Kimata, K.; Shinomura, T.; Habuchi, O.
Molecular cloning and expression of chick chondrocyte chondroitin 6-sulfotransferase
J. Biol. Chem.
270
18575-18580
1995
Gallus gallus (Q92179)
brenda
Habuchi, O.; Hirahara, Y.; Uchimura, K.; Fukuta, M.
Enzymatic sulfation of galactose residue of keratan sulfate by chondroitin 6-sulfotransferase
Glycobiology
6
51-57
1996
Gallus gallus
brenda
Habuchi, O.; Suzuki, Y.; Fukuta, M.
Sulfation of sialyl lactosamine oligosaccharides by chondroitin 6-sulfotransferase
Glycobiology
7
405-412
1997
Gallus gallus
brenda
Kitagawa, H.; Fujita, M.; Ito, N.; Sugahara, K.
Molecular cloning and expression of a novel chondroitin 6-O-sulfotransferase
J. Biol. Chem.
275
21075-21080
2000
Homo sapiens (Q9NS84), Homo sapiens
brenda
Tsutsumi, K.; Shimakawa, H.; Kitagawa, H.; Sugahara, K.
Functional expression and genomic structure of human chondroitin 6-sulfotransferase
FEBS Lett.
441
235-241
1998
Homo sapiens (Q7LGC8), Homo sapiens
brenda
Uchimura, K.; Kadomatsu, K.; Fan, Q.W.; Muramatsu, H.; Kurosawa, N.; Kaname, T.; Yamamura, K.; Fukuta, M.; Habuchi, O.; Muramatsu, T.
Mouse chondroitin 6-sulfotransferase: molecular cloning, characterization and chromosomal mapping
Glycobiology
8
489-496
1998
Mus musculus (O88199), Mus musculus
brenda
Uchimura, K.; Kadomatsu, K.; Nishimura, H.; Muramatsu, H.; Nakamura, E.; Kurosawa, N.; Habuchi, O.; El-Fasakhany, F.M.; Yoshikai, Y.; Muramatsu, T.
Functional analysis of the chondroitin 6-sulfotransferase gene in relation to lymphocyte subpopulations, brain development, and oversulfated chondroitin sulfates
J. Biol. Chem.
277
1443-1450
2002
Mus musculus
brenda
Sawada, T.; Fujii, S.; Nakano, H.; Ohtake, S.; Kimata, K.; Habuchi, O.
Synthesis of sulfated phenyl 2-acetamido-2-deoxy-D-galactopyranosides. 4-O-Sulfated phenyl 2-acetamido-2-deoxy-beta-D-galactopyranoside is a competitive acceptor that decreases sulfation of chondroitin sulfate by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase
Carbohydr. Res.
340
1983-1996
2005
Homo sapiens
brenda
Yamada, T.; Ohtake, S.; Sato, M.; Habuchi, O.
Chondroitin 4-sulphotransferase-1 and chondroitin 6-sulphotransferase-1 are affected differently by uronic acid residues neighbouring the acceptor GalNAc residues
Biochem. J.
384
567-575
2004
Homo sapiens
brenda
Thiele, H.; Sakano, M.; Kitagawa, H.; Sugahara, K.; Rajab, A.; Hoehne, W.; Ritter, H.; Leschik, G.; Nuernberg, P.; Mundlos, S.
Loss of chondroitin 6-O-sulfotransferase-1 function results in severe human chondrodysplasia with progressive spinal involvement
Proc. Natl. Acad. Sci. USA
101
10155-10160
2004
Homo sapiens
brenda
Yusa, A.; Kitajima, K.; Habuchi, O.
N-linked oligosaccharides on chondroitin 6-sulfotransferase-1 are required for production of the active enzyme, Golgi localization, and sulfotransferase activity toward keratan sulfate
J. Biol. Chem.
281
20393-20403
2006
Mus musculus (O88199)
brenda
Liu, J.; Chau, C.; Liu, H.; Jang, B.R.; Li, X.; Chan, Y.; Shum, D.K.
Upregulation of chondroitin 6-sulphotransferase-1 facilitates Schwann cell migration during axonal growth
J. Cell Sci.
119
1196
2006
Rattus norvegicus (Q9QZL2)
brenda
Gruber, H.E.; Ingram, J.; Leslie, K.; Hanley, E.N.
Gene expression of types I, II, and VI collagen, aggrecan, and chondroitin-6-sulfotransferase in the human annulus: in situ hybridization findings
Spine J.
8
810-817
2008
Homo sapiens
brenda
Hermanns, P.; Unger, S.; Rossi, A.; Perez-Aytes, A.; Cortina, H.; Bonafe, L.; Boccone, L.; Setzu, V.; Dutoit, M.; Sangiorgi, L.; Pecora, F.; Reicherter, K.; Nishimura, G.; Spranger, J.; Zabel, B.; Superti-Furga, A.
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis
Am. J. Hum. Genet.
82
1368-1374
2008
Homo sapiens (Q7LGC8), Homo sapiens
brenda
van Roij, M.H.; Mizumoto, S.; Yamada, S.; Morgan, T.; Tan-Sindhunata, M.B.; Meijers-Heijboer, H.; Verbeke, J.I.; Markie, D.; Sugahara, K.; Robertson, S.P.
Spondyloepiphyseal dysplasia, Omani type: further definition of the phenotype
Am. J. Med. Genet. A
146A
2376-2384
2008
Homo sapiens (Q7LGC8), Homo sapiens
brenda
Tuysuz, B.; Mizumoto, S.; Sugahara, K.; Celebi, A.; Mundlos, S.; Turkmen, S.
Omani-type spondyloepiphyseal dysplasia with cardiac involvement caused by a missense mutation in CHST3
Clin. Genet.
75
375-383
2009
Homo sapiens (Q7LGC8)
brenda
Kitagawa, H.; Tsutsumi, K.; Ikegami-Kuzuhara, A.; Nadanaka, S.; Goto, F.; Ogawa, T.; Sugahara, K.
Sulfation of the galactose residues in the glycosaminoglycan-protein linkage region by recombinant human chondroitin 6-O-sulfotransferase-1
J. Biol. Chem.
283
27438-27443
2008
Homo sapiens (Q7LGC8), Homo sapiens
brenda
Tetsukawa, A.; Nakamura, J.; Fujiwara, S.
Identification of chondroitin/dermatan sulfotransferases in the protochordate, Ciona intestinalis
Comp. Biochem. Physiol. B
157
205-212
2010
Ciona intestinalis
brenda
Okuda, H.; Tatsumi, K.; Horii-Hayashi, N.; Morita, S.; Okuda-Yamamoto, A.; Imaizumi, K.; Wanaka, A.
OASIS regulates chondroitin 6-O-sulfotransferase 1 gene transcription in the injured adult mouse cerebral cortex
J. Neurochem.
130
612-625
2014
Mus musculus (O88199), Mus musculus
brenda
Miyata, S.; Kitagawa, H.
Chondroitin 6-sulfation regulates perineuronal net formation by controlling the stability of aggrecan
Neural Plast.
2016
1305801
2016
Mus musculus (O88199)
brenda
Zhou, Z.; Li, Q.; Huang, H.; Wang, H.; Wang, Y.; Du, G.; Chen, J.; Kang, Z.
A microbial-enzymatic strategy for producing chondroitin sulfate glycosaminoglycans
Biotechnol. Bioeng.
115
1561-1570
2018
Rattus norvegicus (Q9QZL2)
brenda
Pan, H.; Xue, W.; Zhao, W.; Schachner, M.
Expression and function of chondroitin 4-sulfate and chondroitin 6-sulfate in human glioma
FASEB J.
34
2853-2868
2020
Homo sapiens (Q7LGC8), Homo sapiens
brenda